Compare Davita Inc (DVA) vs Procter & Gamble Co (PG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Procter & Gamble Co — how do they compare? Davita Inc trades at $230.44 (market cap $14.92B), while Procter & Gamble Co trades at $146.27 (market cap $340.16B). The key difference: Procter & Gamble Co is far larger — about 22.8× Davita Inc's market cap, and Procter & Gamble Co pays a 2.92% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | PG | |
|---|---|---|
Market Cap | $14.92B | $340.16B |
Sector | Health | Consumer Staples |
52-Week High | $235.71 | $167.18 |
52-Week Low | $103.87 | $138.10 |
Enterprise Value | $27.47B | $365.64B |
Volume | — | 6,423,436 |
Dividend Yield | — | 2.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
Procter & Gamble (PG) trades at $148.37, up 0.9% with a neutral technical outlook. The company maintains strong fundamentals with $84.28B revenue and 19.16% net income margin, consistently beating earnings estimates. Recent dividend declaration of $1.09 and WNBA partnership highlight stable returns and brand expansion. Analyst consensus is bullish with 53.85% buy ratings and $161.71 price target, though premium valuation metrics suggest cautious optimism.
PG offers steady growth with reliable dividends but faces margin pressure from rising costs. The stock's premium valuation requires sustained earnings growth to justify upside. Near-term resistance at $150 presents a key level to watch, while support at $145 provides downside protection. Institutional activity remains mixed amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →
